PDF(Sci-hub)
Abstract：
OBJECTIVE: This study aimed to determine the prognostic role of baseline maximum standardized uptake value (SUVmax) obtained by pretreatment PET/CT and the change in SUVmax (ΔSUVmax [%]) in patients with axillary lymph node-positive breast cancer receiving neoadjuvant chemotherapy (NAC).
METHODS: One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAI) and the change in the SUVmax of the breast (ΔSUVmaxB) and axilla (ΔSUVmaxA) were measured. The optimal cut-off value of SUVmax and ΔSUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan-Meier curves.
RESULTS: ΔSUVmaxB, pCRB, pCRA, and pCR parameters were found to be associated with relapse (P < .001, P = .033, P = .016, and P = .013, respectively). ΔSUVmaxB and SUVmaxAI were associated with mortality (P = .001 and P = .006, respectively). Multiple Cox regression analyses revealed that ΔSUVmaxB value was an independent prognostic factor for relapse and mortality (P = .013 and P = .010, respectively).
CONCLUSIONS: The results showed that ΔSUVmaxB was an independent prognostic factor for relapse and mortality in patients with axillary lymph node-positive breast cancer who received NAC.
METHODS: One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAI) and the change in the SUVmax of the breast (ΔSUVmaxB) and axilla (ΔSUVmaxA) were measured. The optimal cut-off value of SUVmax and ΔSUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan-Meier curves.
RESULTS: ΔSUVmaxB, pCRB, pCRA, and pCR parameters were found to be associated with relapse (P < .001, P = .033, P = .016, and P = .013, respectively). ΔSUVmaxB and SUVmaxAI were associated with mortality (P = .001 and P = .006, respectively). Multiple Cox regression analyses revealed that ΔSUVmaxB value was an independent prognostic factor for relapse and mortality (P = .013 and P = .010, respectively).
CONCLUSIONS: The results showed that ΔSUVmaxB was an independent prognostic factor for relapse and mortality in patients with axillary lymph node-positive breast cancer who received NAC.
摘要：
目的：本研究旨在确定在接受新辅助化疗（NAC）的腋窝淋巴结阳性乳腺癌患者中，通过预处理PET/CT获得的基线最大标准化摄取值（SUVmax）和SUVmax的变化（ΔSUVmax[%]）对预后的影响。
方法：本研究评估了180例基线SUVmax患者和121例治疗后SUVmax测量患者。测量乳房（SUVmaxBI）和腋下（SUVmaxAI）的基线SUVmax值以及乳房（ΔSUVmaxB）和腋下（ΔSUVmaxA）的SUVmax变化。通过ROC曲线分析确定SUVmax和ΔSUVmax的最佳截断值。使用Kaplan-Meier曲线计算无病生存期(DFS)和总生存期(OS)。
结果：ΔSUVmaxB，pCRB,pCRA,发现pCR参数与复发相关（分别为P<.001，P=.033，P=.016和P=.013）。ΔSUVmaxB和SUVmaxAI与死亡率相关（分别为P=.001和P=.006）。多重Cox回归分析显示，ΔSUVmaxB值是复发和死亡率的独立预后因素（分别为P=0.013和P=.010）。
结论：结果显示，ΔSUVmaxB是腋窝淋巴结阳性乳腺癌患者接受NAC治疗后复发和死亡的独立预后因素。
方法：本研究评估了180例基线SUVmax患者和121例治疗后SUVmax测量患者。测量乳房（SUVmaxBI）和腋下（SUVmaxAI）的基线SUVmax值以及乳房（ΔSUVmaxB）和腋下（ΔSUVmaxA）的SUVmax变化。通过ROC曲线分析确定SUVmax和ΔSUVmax的最佳截断值。使用Kaplan-Meier曲线计算无病生存期(DFS)和总生存期(OS)。
结果：ΔSUVmaxB，pCRB,pCRA,发现pCR参数与复发相关（分别为P<.001，P=.033，P=.016和P=.013）。ΔSUVmaxB和SUVmaxAI与死亡率相关（分别为P=.001和P=.006）。多重Cox回归分析显示，ΔSUVmaxB值是复发和死亡率的独立预后因素（分别为P=0.013和P=.010）。
结论：结果显示，ΔSUVmaxB是腋窝淋巴结阳性乳腺癌患者接受NAC治疗后复发和死亡的独立预后因素。
